General
Preferred name
CANGRELOR
Synonyms
CANGRELOR TETRASODIUM ()
Cangrelor (AR-C69931) ()
Kangreal ()
AR-C69931XX ()
Cangrelor ()
Kengreal ()
AR-C69931MX ()
Kengrexal ()
Cangrelor tetrasodium salt ()
Cangrelor (sodium salt) ()
P&D ID
PD009299
CAS
163706-36-3
163706-06-7
63706-36-3
Tags
natural product
drug
available
Approved by
EMA
FDA
First approval
2015
Drug Status
approved
Drug indication
Thrombosis
Max Phase
Phase 4
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Cangrelor is an intravenously administered antiplatelet compound.
(GtoPdb)
DESCRIPTION
Cangrelor, an adenylic acid derivative, has been found to be a P2Y12 inhibitor that could be effective in some coronary artery diseases. It is approved by FDA as an antiplatelet drug. It has been used to reduce the risk of heart attack during cardiology procedures.
(BOC Sciences Bioactive Compounds)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
1
Organisms
0
Compound Sets
23
AdooQ Bioactive Compound Library
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Guide to Pharmacology
LSP-MoA library (Laboratory of Systems Pharmacology)
Natural product-based probes and drugs
NCATS Inxight Approved Drugs
ReFrame library
TargetMol Bioactive Compound Library
ZINC Tool Compounds
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
53
Molecular Weight
774.95
Hydrogen Bond Acceptors
15
Hydrogen Bond Donors
7
Rotatable Bonds
15
Ring Count
3
Aromatic Ring Count
2
cLogP
2.85
TPSA
255.91
Fraction CSP3
0.71
Chiral centers
6.0
Largest ring
6.0
QED
0.05
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
Endocrinology/Hormones
GPCR/G protein
Target
GPR17
Indication
myocardial infarction
MOA
purinergic receptor antagonist
Biosynthetic Origin
Nucleoside
Therapeutic Indication
Coronary Artery Disease
Therapeutic Class
Cardiovascular
Source data
